semaglutide glp-1 ozempic in newport beach medications are becoming one of the most talked-about topics medicine—and not just for weight management., Emerging research is exploring how GLP-1 therapies may have applications beyond Explore Our Ozempic Weight Loss

Berberine (BBR) exhibits significant anti-diabetic effects by enhancing insulin sensitivity, promoting glycolysis, and inhibiting gluconeogenesis

Retatrutide hit 28.3% weight loss in the May 2026 trial

Proven results

Key Benefits

Aims/hypothesis Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) in individuals taking liraglutide and semaglutide

Each has demonstrated the potential to emerge as either a Best-in-Class or First-in-Class treatment in the obesity field.The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies. HM15275: Next-Generation Triple Agonist Targeting Quantity and Quality of Weight LossHM15275 is engineered to optimize the activity balance of GLP-1, GIP, and glucagon (GCG) receptors, delivering targeted obesity treatment while also addressing comorbid metabolic conditions such as diabetes, cardiovascular, and renal disease